

1 **Editorial**

2 **Title: Time for an Alzheimer’ s disease cocktail**

3 *[Suggestions: No more than 20 words. No abbreviations except for standardized ones e.g., DNA, RNA, gene or*
4 *protein names, etc.]*

5 **Forename Surname^a, Forename Surname^{a,b}, Forename Surname^c**

6 ^a *Department, Institution, City Postcode, Country.*

7 ^b *Department, Institution, City, State Postcode, Country.*

8 ^c *Department, Institution, City Postcode, Province, Country.*

9 **Correspondence to:** Prof./Dr. Forename Surname, Department, Institution, Detailed Address, City Postcode,
10 Country.

11 E-mail: xxxx@xxxx.xxx

12 **How to Use This Template**

13 *This template shows the manuscript structure that can be used in an original article: Abstract, Keywords,*
14 *Introduction, Methods, Results, Discussion, Declarations and References. Please note that each part has a*
15 *corresponding style, which authors should follow. Please note that the fonts in gray show writing requirements.*
16 *For any questions, you may contact the [editorial office](#).*

17

18 **Abstract**

19 *[Suggestions: No more than 250 words. No citations. Define abbreviations at their first mention.]*

20 Abstract is a brief summary of an article, which helps the readers quickly ascertain the paper's main
21 content. In this part, authors may mention writing purpose, experimental methods, results and their
22 significance in this research field, *etc.*

23 **Keywords:** Aging, older patients, chronic heart failure, drug therapy

24 *[Please suggest 3-6 keywords which can be used for describing the content of the manuscript and will enable the*
25 *full text of the manuscript to be searchable online.]*

26

27 **LEVEL 1 HEADING**

28 [e.g., MAIN TEXT]

29 In this section, authors should describe the main text of the review in detail. It may contain a summary of
30 representative studies in a specific field, the methods, results in previous studies, their advantages and
31 disadvantages, authors’ opinions on the topic, *etc.* We suggest that authors may set headings (level 1
32 heading, level 2 heading, level 3 heading, *etc.*) to separate different cases or situations.

33 **Level 2 heading**

34 [e.g., Statistical analyses]

35 *Level 3 heading*

36 [e.g., Data distributions, outliers and linear regression]

37 *Tips:*

- 38 ● *All drugs and chemicals used, including generic name(s), dose(s), and route(s) of administration, should be*
39 *identified precisely;*

- 40 ● *When reporting studies on human beings or animals, authors should strictly follow the Helsinki*
 41 *Declaration (available at <http://www.wma.net/en/30publications/10policies/b3/>) and other related publishing*
 42 *ethical standards.*

43 **Table 1** (other forms: Tables 1 and 2; Tables 1-3), **Equation (1)** [other forms: Equations (2) and (3);
 44 Equations (4-6)] and **Figure 1** (other forms: Figure 1A and B; Figure 2A-C; Figures 1 and 2A; Figures 1,
 45 2A and 3-5) show the examples of diagrams. All the tables, equations and figures should be cited in
 46 sequence in the main content near to the first time they appear. For supplementary material, authors may
 47 cite table, equation and figure like **Supplementary Table 1**, **Supplementary Equation (1)** and
 48 **Supplementary Figure 1**.

49 *Tips:*

- 50 ● *Results should be presented in a logical sequence;*
 51 ● *Avoid redundant explanations to all the data from the tables or illustrations.*

52 **Table 1. This is a table caption. A summary description of this table should be written here**

Authors	Regimen	<i>n</i>	Age (year)	CR (%)	2-year (3-year) EFS/PFS (%)	2-year (3-year) OS (%)
Our current study	CHOP	251	17-82	69.8	55.3 (46.0)	58.0 (52.0)
	CVP	67	45-87	29.9*	18.0 (12.0)*	25.0 (19.0)*
Khaled <i>et al.</i> ^[1]	CHOP	40	19-75	67	54 (54)	82 (71)
Burton <i>et al.</i> ^[2]	CHOP	105	22-66	70	4-year PFS: 56	4-year OS: 65
	CIOP	106	25-67	52	4-year PFS: 40*	4-year OS: 56 [#]

53 This part is footer. **P* < 0.05, [#]*P* ≥ 0.05. EFS: event-free survival; PFS: progression-free survival; OS: overall survival; CHOP:
 54 cyclophosphamide, doxorubicin, vincristine, and prednisone; CVP: cyclophosphamide, vincristine, and prednisone; CIOP:
 55 cyclophosphamide, idarubicin, vincristine, and prednisone; CR: complete response. This table is cited with permission from Li *et*
 56 *al.*^[1] published in xxx


57 *Table notes:*

- 58 ● *Tables should be cited in numeric order and placed after the paragraph where it is first cited;*
 59 ● *The table caption should be placed above the table and labeled sequentially (e.g., Table 1, Table 2);*
 60 ● *Tables should be provided in editable form like DOC or DOCX format (picture is not allowed);*
 61 ● *Abbreviations and symbols used in table should be explained in footnote;*
 62 ● *Explanatory matter should also be placed in footnotes;*
 63 ● *Non-English words should be avoided;*
 64 ● *Permission for use of copyrighted materials from other sources, including re-published, adapted, modified,*
 65 *or partial tables from the internet, must be obtained. It is authors' responsibility to acquire the licenses, to*
 66 *follow any citation instruction requested by third-party rights holders, and cover any supplementary*

$$S_i = \sum_{j=1}^n W_j X_j \quad (1)$$

67 *Equation note:*

- 68 ● *Equations should be provided in editable form (image file format is not allowed).*



69 **Figure 1.** We present examples of electron micrograph, non-editable and editable images in Figure 1A-C.
 70 A: description of what the Figure 1A is; B: description of what the Figure 1B is; C: description of what
 71 the Figure 1C is.

72 *Figure notes:*

- 73 ● *Figures should be cited in numeric order (e.g., Figure 1, Figure 2) and placed after the paragraph where it*
 74 *is first cited;*
- 75 ● *Figures can be submitted in format of tiff, psd, AI or jpeg, with resolution of 300-600 dpi;*
- 76 ● *Diagrams with describing words (including, flow chart, coordinate diagram, bar chart, line chart, and*
 77 *scatter diagram, etc.) should be editable in word, excel or powerpoint format. Non-English information*
 78 *should be avoided;*
- 79 ● *Please use the font in “Times New Roman” format for the text in the chart*
- 80 ● *Labels, numbers, letters, arrows, and symbols in figure should be clear, of uniform size, and contrast with*
 81 *the background;*
- 82 ● *Symbols, arrows, numbers, or letters used to identify parts of the illustrations must be identified and*
 83 *explained in the legend;*
- 84 ● *Internal scale (magnification) should be explained and the staining method in photomicrographs should be*
 85 *identified;*
- 86 ● *All non-standard abbreviations should be explained in the legend;*
- 87 ● *Authors should pay attention to the protection of patients’ rights, such as privacy and portrait, and obtain*
 88 *signed patient consent from authors before using any personal information of patients. The patient’s*
 89 *portrait with full characters and his/her real name is not allowed for use;*
- 90 ● *Permission for use of copyrighted materials from other sources, including re-published, adapted, modified,*
 91 *or partial figures and images from the internet, must be obtained. It is authors’ responsibility to acquire the*
 92 *licenses, to follow any citation instruction requested by third-party rights holders, and cover any*
 93 *supplementary charges.*

94 CONCLUSION

95 In this part, authors should summarize the principle conclusions of the study. In details, it may contain a
96 summary of key findings, a statement about strengths and limitations of the studies, or the implications
97 of the work for future research, *etc.* An attractive and interesting conclusion is always welcome.

98 *Tips:*

- 99 ● *Avoid redundant explanations to data or other materials given in the Introduction or the Results section;*
- 100 ● *Contributors should avoid making statements on economic benefits and costs except for economic data and*
101 *analyses that serve as an integral part of the manuscript.*

102 DECLARATIONS

103 Acknowledgments

104 Anyone who contributed towards the article but does not meet [the criteria](#) for authorship, including
105 those who provided professional writing services or materials, should be acknowledged. Authors should
106 obtain permission to acknowledge from all those mentioned in the Acknowledgments section. This
107 section is not added if the author does not have anyone to acknowledge.

108 Authors' contributions

109 Single author:

110 The author contributed solely to the article.

111 Two or more authors:

112 Made substantial contributions to conception and design of the study and performed data analysis and
113 interpretation: Salas H, Castaneda WV;

114 Performed data acquisition, as well as provided administrative, technical, and material support: Castillo
115 N, Young V

116 ...

117 Availability of data and materials

118 Authors should declare where the data supporting their findings can be found. Data can be deposited into
119 data repositories or published as supplementary information in the journal. Authors who cannot share
120 their data should state that the data will not be shared and explain it.

121 If a manuscript does not involve such issue, please state "Not applicable." in this section.

122 Financial support and sponsorship

123 If there are sources of funding for the study reported, any relevant grant numbers and the link of funder's
124 website should be provided if any. The role of the funding body in the experiment design, collection,
125 analysis and interpretation of data, and writing of the manuscript should be declared:

126 This work was supported by Grant name XX (No. XXXX; No. XXX)...

127 If there is no grant:

128 None.

129 Conflicts of interest

130 If there are any potential conflicts of interest that may be perceived as inappropriately influencing the
131 representation or interpretation of reported research results, please declare here.

132 If not, please write as "All authors declared that there are no conflicts of interest."

133 Some authors may be bound by confidentiality agreements. In such cases, in place of itemized
134 disclosures, we will require authors to state "All authors declare that they are bound by confidentiality
135 agreements that prevent them from disclosing their conflicts of interest in this work."

136 If authors are unsure whether conflicts of interest exist, please refer to the “Conflicts of Interest” of ANT
137 [Editorial Policies](#) for a full explanation.

138 **Ethical approval and consent to participate**

139 Research involving human subjects, human material or human data must be performed in accordance
140 with the [Declaration of Helsinki](#) and approved by an appropriate ethics committee. An informed consent
141 to participate in the study should also be obtained from participants, or their parents or legal guardians
142 for children under 16. A statement detailing the name of the ethics committee (including the reference
143 number where appropriate) and the informed consent obtained must appear in the manuscripts reporting
144 such research.

145 Studies involving animals and cell lines must include a statement on ethical approval. More
146 information is available at [Editorial Policies](#).

147 If the manuscript does not involve such issue, please state “Not applicable.” in this section.

148 **Consent for publication**

149 Manuscripts containing individual details, images or videos, must obtain consent for publication from
150 that person, or in the case of children, their parents or legal guardians. If the person has died, consent for
151 publication must be obtained from the next of kin of the participant. Manuscripts must include a
152 statement that a written informed consent for publication was obtained. Authors do not have to submit
153 such content accompanying the manuscript. However, these documents must be available if requested.

154 If the manuscript does not involve this issue, state “Not applicable.” in this section.

155 **Copyright**

156 Authors retain copyright of their works through a Creative Commons Attribution 4.0 International
157 License that clearly states how readers can copy, distribute, and use their attributed research, free of
158 charge. Authors are required to sign License to Publish before formal publication.

159 **REFERENCES**

160 Identify references in the text by alphabetic numerals e. g. [1-3] or [1, 2]. The reference list should be
161 separated from the text; references must be numbered consecutively in the order in which they are
162 mentioned in the text. Use the style of the examples below, which are based on the formats used by the
163 NLM in Index Medicus. The titles of journals should be abbreviated according to the style used in Index
164 Medicus. Use complete name of the journal for non-indexed journals. Avoid using abstracts as references.
165 Information from manuscripts submitted but not accepted should be cited in the text as "unpublished
166 observations" with written permission from the source. Avoid citing a "personal communication" unless
167 it provides essential information not available from a public source, in which case the name of the person
168 and date of communication should be cited in parentheses in the text.

169 **Reference to a journal publication:**

170 Ormsbee MJ, Prado CM, Ilich JZ, Purcell S, Siervo M, Folsom A, *et al.* Osteosarcopenic obesity: the role
171 of bone, muscle, and fat on health. *J Cachexia Sarcopenia Muscle*, 2014, 5(3): 183-192.

172 **Reference to a book**

173 Voet D, Voet JG. *Biochemistry*. New York: John Wiley & Sons 1990. 1223 p.

174 **Reference to a website**

175 Cancer Research UK, 1975. Cancer statistics reports for the UK.
176 <http://www.cancerresearchuk.org/aboutcancer/statistics/cancerstatsreport/> (accessed 13.03.03).

177 *For other types of references please refer to U.S. National Library of Medicine*
178 *(https://www.nlm.nih.gov/bsd/uniform_requirements.html). The names of journals should be *Italic*.*

179 The journal also recommends that authors prepare references with a bibliography software package, such
180 as EndNote to avoid typing mistakes and duplicated references.

181 **Supplementary Materials**

182 Additional data and information can be uploaded as Supplementary Materials to accompany the
183 manuscripts. The supplementary materials will also be available to the referees as part of the peer-review
184 process. Any file format is acceptable, such as data sheet (word, excel, csv, cdx, fasta, pdf or zip files),
185 presentation (powerpoint, pdf or zip files), image (cdx, eps, jpeg, pdf, png or tiff), table (word, excel, csv
186 or pdf).